Literature DB >> 28808084

Glycopyrronium for severe drooling in children.

.   

Abstract

Drooling of saliva is common in children with physical, intellectual and learning disability, and with poor neuromuscular coordination and oral control.1 It can cause skin breakdown, damage to clothes and equipment and psychosocial problems for the child and family. For many years, glycopyrronium has been prescribed off-label using the injection solution given orally or tablets crushed and suspended in water, or as unlicensed products that were imported or manufactured as pharmaceutical specials.2,3 In January 2017, a glycopyrronium oral solution (Sialanar-Proveca Limited) became available in the UK as the first licensed product for the treatment of severe drooling (sialorrhoea) in children and adolescents aged 3 years and older with chronic neurological disorders.4-6 Here, we consider the place of this new product in the management of severe drooling. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28808084     DOI: 10.1136/dtb.2017.8.0517

Source DB:  PubMed          Journal:  Drug Ther Bull        ISSN: 0012-6543


  2 in total

1.  Glycopyrrolate for drooling in children with medical complexity under three years of age.

Authors:  Eleonora Lovardi; Maria Antonietta De Ioris; Donatella Lettori; Caterina Geremia; Susanna Staccioli; Gessica Della Bella; Raffaella Scrocca; Alessia Scarselli; Marcella Aversa; Francesco De Peppo; Andrea Campana; Enrico Castelli
Journal:  Ital J Pediatr       Date:  2022-01-08       Impact factor: 2.638

2.  Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience.

Authors:  Davide Zanon; Cristina Tumminelli; Anna Maria Chiara Galimberti; Lucio Torelli; Alessandra Maestro; Egidio Barbi; Natalia Maximova
Journal:  Ital J Pediatr       Date:  2021-11-06       Impact factor: 2.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.